Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytek Biosciences reported Q1 2024 earnings with an adjusted EPS of $(0.05), missing the $(0.04) estimate, but sales of $44.900M exceeded the $43.586M estimate, marking a 21.06% increase from the previous year.
May 08, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cytek Biosciences missed EPS estimates by 25% but exceeded sales forecasts by 3.01%, showing significant year-over-year sales growth.
The miss in EPS estimates could negatively impact investor sentiment, while the beat on sales forecasts and significant year-over-year growth could counterbalance this with a positive outlook on the company's revenue growth. The mixed results present a neutral short-term impact as investors weigh the implications of earnings misses against sales beats.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100